{
  "schemaVersion": 1,
  "id": "research-375",
  "slug": "375-what-a-randomized-extension-showed-when-participants-switched-to-placebo",
  "title": "What a randomized extension showed when participants switched to placebo",
  "catalogLabel": "Tesamorelin",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tesamorelin",
  "productHandles": [
    "tesamorelin-676",
    "tesamorelin-538",
    "tesamorelin-675"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tesamorelin-676",
    "https://heritagebiolabs.com/product/tesamorelin-538",
    "https://heritagebiolabs.com/product/tesamorelin-675"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 323,
  "sourceYears": [
    2010,
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. Some resemble the natural messages that regulate hormone release. Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with an added chemical group at its starting end. An older clinical trial used a second randomized phase to ask what happened to abdominal visceral fat when participants continued the study treatment or switched to placebo. [1, 2]",
    "No recent primary report of this exact continuation and withdrawal comparison was identified. The older study enrolled 404 adults with HIV and excess abdominal fat in the context of antiretroviral treatment. In the first six months, participants were assigned to tesamorelin or placebo. The researchers used imaging to measure fat stored around internal organs. On average, visceral fat fell more in the tesamorelin group than in the placebo group during this first phase. [1]",
    "In the extension, people initially receiving tesamorelin were assigned again, either to continue or to switch to placebo. The comparison helps distinguish an effect that persists after exposure ends from one that depends on continued exposure during the observation period. The investigators reported that reductions in visceral fat were maintained or deepened among participants who continued, while the initial changes were rapidly lost in the group that switched to placebo. [1]",
    "The outcome was visceral fat measured with imaging. That result is different from an outcome for body weight or fat in other places. It also does not establish whether the observed differences would affect heart disease or other events years later. Those are separate questions that require longer follow-up and a study designed to capture them. [1, 2]",
    "The original trial and its extension help explain the evidence behind the defined U.S. indication for excess abdominal fat in adults with HIV-associated lipodystrophy. The continuation and withdrawal results describe the study groups and observation period. They do not predict the course for every individual or provide evidence for general weight management. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes (publication 2010-03).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20101189/"
    },
    {
      "number": 2,
      "citation": "Theratechnologies. EGRIFTA WR- tesamorelin kit. U.S. prescribing information on DailyMed (updated 2026-07-29).",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/375-what-a-randomized-extension-showed-when-participants-switched-to-placebo",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/375-what-a-randomized-extension-showed-when-participants-switched-to-placebo.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/375-what-a-randomized-extension-showed-when-participants-switched-to-placebo.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 075 - Tesamorelin.docx",
    "sourceArticleNumber": 375,
    "contentSha256": "2d1c584e4c2b02cfd932e066141e8de2eba042a733a7bdc79b19b7c6e749e9d1",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
